ABSTRACT
ESV have already been successfully used for the treatment of degenerated bioprosthesis with severe regurgitation (Fig. 42.20). The use of TAVI for this indication is limited by the inner diameter of the previously implanted valve and a potential infectious etiology of the degeneration of the valve that needs to be ruled out before intervention. Aortic regurgitation represents another possible indication for TAVI but is limited by the usually mild calcification of the valve and the often associated dilated ascending aorta.
